Management of renal dysfunction in the liver transplant recipient

Current Opinion in Organ Transplantation

Volumn 14, Issue 3, 2009, Pages 231-239

  Pham, Phuong Thu T ^a   Pham, Phuong Chi T ^b   Wilkinson, Alan H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Calcineurin inhibitor toxicity; Chronic kidney disease; Liver transplant; Renal dysfunction

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BASILIXIMAB; BILIRUBIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; RECEPTOR BLOCKING AGENT; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VERAPAMIL; IMMUNOSUPPRESSIVE AGENT;

BACTERIAL PERITONITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEPATORENAL SYNDROME; HUMAN; HYPOALBUMINEMIA; HYPOPROTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; PARACENTESIS; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; CHRONIC DISEASE; DISEASE COURSE; MORTALITY; PATIENT SELECTION; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; CHRONIC DISEASE; DISEASE PROGRESSION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER TRANSPLANTATION; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649373847     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832b34a4     Document Type: Review

References (49)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940. (Pubitemid 37064766)
2. Pham PT, Pham PC, Wilkinson AH. Renal failure in adult liver transplant recipients. In: Busuttil RW, Klintmalm GB, editors. Transplantation of the liver, 2nd ed. Philadelphia, Pennsylvania: Elsevier Saunders; 2005. pp. 891-914.
3. Contreras G, Garces G, Quartin AA, et al. An epidemiology study of early renal replacement therapy after orthotopic liver transplantation. J Am Soc Nephrol 2002; 13:228-233. (Pubitemid 34042032)
4. Runyon BA, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39:841-856.
5. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomized pilot study. Gut 2002; 50:90-94. (Pubitemid 34028309)
6. Singh V, Kumar R, Nain CK, et al. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006; 21 (1 Pt 2):303-307.
7. Ruiz del Arbol L, Monescillo A, Jimenez W, et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113:579-586. (Pubitemid 27351786)
8. Ghassemi S, Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21:77-93. This article provides a concise review of the pathogenesis and clinical diagnosis of SBP and its prevention and management. The rationale for albumin therapy in patients with SBP and concomitant AKI and the role of prophylactic antibiotics in high-risk populations are also discussed. (Pubitemid 46076000)
9. Fernandez J, Monteagudo J, Bargallo X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42:627-634. (Pubitemid 41233655)
10. Sigal SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007; 56:597-599. (Pubitemid 46580522)
11. Fasolato S, Angeli P, Dallagnese L. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45:223-229. The results of the study show that biliary or gastrointestinal infections, SBP, and urinary tract infection can precipitate acute progressive kidney injury in patients with cirrhosis and ascites. (Pubitemid 46144382)
12. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20:1495-1501. (Pubitemid 24359062)
13. Cabezuelo JB, Ramirez P, Rios A, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69:10073-11080. (Pubitemid 43372183)
14. Koo M, Sabate A, Ramos E, et al. Factors related to renal dysfunction after liver transplantation in patients with normal preoperative function. Rev Esp Anestesiol Reanim 2006; 53:538-544.
15. Cabezuelo JB, Ramirez P, Acosta F, et al. Does the standard vs. piggyback surgical technique affect the development of acute renal failure after orthotopic liver transplantation? Transplant Proc 2003; 35:1913-1914.
16. Gallardo ML, Gutirrez MEH, Perez GS, et al. Risk factors for renal dysfunction in the postoperative course of liver transplant. Liver Transpl 2004; 10:1379-1385. (Pubitemid 39530053)
17. Tchervenkov JI, Tzimas GN, Cantarovich M, et al. The impact of thymoglobulin on renal function and calcineurin inhibitor in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 2004; 36:1747-1752. (Pubitemid 39200418)
18. Bajjoka I, Hsaiky L, Brown K, et al. Preserving renal function in liver transplant recipients with rabbit-antithymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl 2008; 14:66-72. This retrospective cohort study shows that induction therapy with antithymocyte globulin and delayed initiation of CNI by only 4.5 days result in significant improvement in renal function throughout the first year after transplant compared with controls (i.e. no induction and early initiation of CNI). Of interest, the use of antibody induction therapy is associated with a significantly lower incidence of infection compared with controls. More importantly, antithymocyte globulin is not associated with an increased incidence of hepatitis C recurrence. Nonetheless, it should be noted that the long-term impact of antibody induction on HCV-associated recurrent graft hepatitis is currently unknown and awaits further studies. (Pubitemid 351167991)
19. Soliman T, Hertz H, Burghuber C, et al. Short-term induction therapy with antithymocyte and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007; 13:1039-1044. (Pubitemid 47189018)
20. Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69:307-311. (Pubitemid 30075292)
21. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11:1064-1072.
22. Lin C-C, Chuang F-R, Lee C-H, et al. The renal sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl 2005; 11:1258-1264. (Pubitemid 41511941)
23. Zaghla H, Selby RR, Chan LS, et al. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther 2006; 23:513-520. (Pubitemid 43382006)
24. Velidedeoglu E, Desai CNM, Campos L, et al. Predictors of late kidney dysfunction postliver transplantation. Transplant Proc 2002; 34:3315-3316. (Pubitemid 35463331)
25. Gonwa TA, Mai MI, Melton MB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy. Transplantation 2001; 72:1934-1939.
26. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940. (Pubitemid 37064766)
27. Gayowski T, Singh N, Keyes L, et al. Late-onset renal failure after liver transplantation: role of posttransplant alcohol use. Transplantation 2000; 3:383-388. (Pubitemid 30118119)
28. Gournay J, Ferrell LD, Roberts JP, et al. Cryoglobulinemia presenting after liver transplantation. Gastroenterology 1996; 110:265-270.
29. Cantarovich M, Tzimas GN, Barkun J, et al. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term livertransplant patients with renal dysfunction. Transplantation 2003; 15:98-102. (Pubitemid 36877122)
30. Reich DJ, Clavien PA, Hodge EE, et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 2005; 80:18-25. (Pubitemid 40980890)
31. Jain A, Vekatramanan R, Eghtesad B, et al. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 2005; 80:859-864. (Pubitemid 41443771)
32. Neau-Cransac M, Morel D, Bernard P-H, et al. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002; 16:368-373.
33. Barkmann A, Nashan B, Schidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69:1886-1890. (Pubitemid 30340350)
34. Schiltt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: a randomized controlled study. Lancet 2001; 357:587-591. (Pubitemid 32179611)
35. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75:186-190. (Pubitemid 36139669)
36. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357:609-610. (Pubitemid 32179620)
37. Schmitz V, Laudi S, Moeckel F, et al. Chronic renal dysfunction following liver transplantation. Clin Transplant 2008; 22:333-340. (Pubitemid 351689664)
38. Pageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12:1755-1760. (Pubitemid 44920019)
39. Manrique A, Jimenez C, Ortega P, et al. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Transplant Proc 2008; 40:2962-2964. In this article, the authors analyze the influence of MMF monotherapy on the clinical course of recurrent hepatitis C. No significant changes in liver function tests were seen after conversion from CNI to MMF monotherapy. However, transient improvement in renal function and BP were observed.
40. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9:126-129. (Pubitemid 36204562)
41. Sanchez EQ, Martin AP, Ikegami T, et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005; 37:4416-4423. (Pubitemid 43016046)
42. Watson CJE, Gimson AES, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13:1694-1702. This is one of the first randomized controlled trials to assess the safety and efficacy of CNI-to-sirolimus conversion for renal sparing in liver transplant recipients. In addition, GFR is measured by 51Cr-EDTA clearance, which is the gold standard for GFR estimation.
43. Di Benedetto F, Di Sandro S, De Ruvo N, et al. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction owing to calcineurin inhibitors. J Clin Gastroenterol 2008 Dec 3. [Epub ahead of print]
44. Yang YJ, Chen LX, Li LX, et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. Transplant Proc 2008; 40:1541-1544. This article demonstrates that tacrolimus-to-sirolimus conversion therapy is well tolerated and effective in stable OLT recipients with tacrolimus-related chronic renal insufficiency at a median follow-up of 2.4 years. Conversion was performed at a median of 8.5 months after OLT. The authors suggest that conversion is well tolerated when timed appropriately, and chronic nephrotoxicity may be ameliorated by early conversion.
45. Yu S, He X, Yang L, et al. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Exp Clin Transplant 2008; 6:113-117. The authors demonstrate that sirolimus conversion therapy resulted in significant improvement in renal function. However, in the early postoperative period, sirolimus combination therapy with either a CNI or MMF is recommended to prevent acute rejection.
46. Shenoy S, Hardinger KL, Crippin J, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2007; 83:1389-1392.
47. Dubay D, Smith RJ, Qiu KG, et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008; 14:651-659. These authors were among the first to compare sirolimus conversion for renal preservation using a well matched CNI reduction control arm. The authors demonstrate that conversion to sirolimus in liver transplant patients with chronic renal insufficiency is associated with stabilization of renal function but confers no additional benefit to low-dose CNIs. In contrast, conversion therapy may be disadvantageous in patients with a CrCl of less than 30 ml/min. Large-scale, multicenter, randomized controlled trials are still needed.
48. Stratta P, Canavese C, Quaglia M, et al. Posttransplantation chronic renal damage in nonrenal transplant recipients. Kidney Int 2005; 68:143-146. (Pubitemid 43169892)
49. Lassila M, Finckenberg P, Pere AK, et al. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br J Pharmacol 2000; 130:1339-1347. (Pubitemid 30488598)